Patent application number | Description | Published |
20110104657 | METHOD OF DETECTING MALIGNANCY OF NASOPHARYNGEAL CARCINOMA AND A NASOPHARYNGEAL CARCINOMA MALIGNANCY BIOMARKER - A method of detecting malignancy of nasopharyngeal carcinoma and a nasopharyngeal carcinoma malignancy biomarker are disclosed. Firstly, a specimen is obtained from a testee. Next, the specimen is tested for its MIP-3α expression level. Then, the MIP-3α expression level of the specimen is compared with that of a control. Finally, the malignancy of nasopharyngeal carcinoma is determined according to a relative MIP-3α expression level between the specimen and the control. | 05-05-2011 |
20130011867 | BLADDER CANCER BIOMARKER AND TEST METHOD USING THE SAME - A bladder cancer biomarker and a test method using the same are provided. The biomarker contains serum amyloid A-4 protein (SAA4), which exist in the urine specimen of a testee. The expression intensity of the biomarker can facilitate diagnosis of bladder cancer and evaluation of aggressiveness and malignancy of bladder cancer. Thereby, the physician can arrange an optimized treatment to achieve the best therapeutic effect. | 01-10-2013 |
20130084582 | SEROLOGICAL MARKERS FOR DETECTING COLORECTAL CANCER AND THEIR APPLICATION FOR INHIBITING COLORECTAL CANCER CELLS - Embodiments relate to serological markers for detecting the colorectal cancer and applications of the serological markers. A phospholipid scramblase1 (PLSCR1), a stomatin-like protein 2 (STOML2) or a transport protein Sec61β (SEC61β) increases expression in the blood at the earlier stage of the colorectal cancer. Detecting the expression of the PLSCR1, STOML2 or SEC61β protein or an induced autoantibody of each protein in a blood sample is used to diagnose the colorectal cancer. Moreover, the serological marker improves the detection efficiency and the sensitivity in detecting the colorectal cancer and is used to predict the prognosis. The serological markers are applied in preparing a detection device or inhibiting the growth of the colorectal cancer cells. | 04-04-2013 |
20130236913 | SEROLOGICAL MARKERS FOR DETECTING COLORECTAL CANCER AND THEIR APPLICATION FOR INHIBITING COLORECTAL CANCER CELLS - Embodiments relate to serological markers for detecting the colorectal cancer and applications of the serological markers. A phospholipid scramblase (PLSCR1), a stomatin-like protein 2 (STOML2) or a transport protein Sec61β (SEC61β) increases expression in the blood at the earlier stage of the colorectal cancer. Detecting the expression of the PLSCR1, STOML2 or SEC61β protein or an induced autoantibody of each protein in a blood sample is used to diagnose the colorectal cancer. Moreover, the serological marker improves the detection efficiency and the sensitivity in detecting the colorectal cancer and is used to predict the prognosis. The serological markers are applied in preparing a detection device or inhibiting the growth of the colorectal cancer cells. | 09-12-2013 |
20130260479 | DEVICE AND METHOD FOR DETECTING EXISTENCE OF TARGET BIOMOLECULES IN A SPECIMEN - A detecting device is used for detecting existence of target biomolecules in a specimen with use of antibody complexes labeled with fluorescent molecules. The detecting device includes a capture member coated with capture antibodies for immobilizing the antibody complexes on the capture member when the target biomolecules exist in the specimen, a light emitting unit emitting a beam for exciting the fluorescence molecules to generate a fluorescence signal, and a signal processing unit for receiving the fluorescence signal and determining existence of the target biomolecules in the specimen based upon receipt of the fluorescence signal. | 10-03-2013 |
20130266970 | PLASMA BIOMARKER FOR DISTAL METASTASIS IN COLORECTAL CANCER - The present invention proposes secretory gelsolin (pGSN) as a plasma biomarker for evaluating distal metastasis of colorectal cancer. The present invention uses a special amino acid sequence of pGSN to fabricate a pGSN-specific polyclonal antibody. The present invention further uses the pGSN-specific polyclonal antibody to develop a high-specificity ELISA method and an assay kit thereof for evaluating distal metastasis of colorectal cancer. | 10-10-2013 |
Patent application number | Description | Published |
20110020846 | Oral cancer biomarker and inspection method using the same - The present invention discloses an oral cancer biomarker and an inspection method using the same. The biomarker is Mca-2 binding protein (Mac-2BP), which can be directly detected in the specimen of the body fluid of a testee, and which can realize a fast and effective clinical diagnosis of oral cancer. | 01-27-2011 |
20110021750 | Oral cancer biomarker and inspection method using the same - The present invention discloses an oral cancer biomarker and an inspection method using the same. The biomarker is Mca-2 binding protein (Mac-2BP), which can be directly detected in the specimen of the body fluid of a testee, and which can realize a fast and effective clinical diagnosis of oral cancer. | 01-27-2011 |
20110105723 | Method of Detecting Malignancy of Nasopharyngeal Carcinoma and A Nasopharyngeal Carcinoma Malignancy Biomarker - A method of detecting malignancy of nasopharyngeal carcinoma and a nasopharyngeal carcinoma malignancy biomarker are disclosed. Firstly, a specimen is obtained from a testee. Next, the specimen is tested for its MIP-3α expression level. Then, the MIP-3α expression level of the specimen is compared with that of a control. Finally, the malignancy of nasopharyngeal carcinoma is determined according to a relative MIP-3α expression level between the specimen and the control. | 05-05-2011 |
20110195478 | BLADDER CANCER BIOMARKER AND TEST METHOD USING THE SAME - The present invention discloses a bladder cancer biomarker and a test method using the same. The biomarker contains at least one of the mentioned 69 compounds, such as apolipoprotein A1 (APOA1), apolipoprotein A2 (APOA2), peroxiredoxin 2 (PRDX2), heparin cofactor 2 precursor (HCII), and serum amyloid A-4 protein (SAA4), which exist in the urine specimen of a testee. The expression intensity of the biomarker can facilitate diagnosis of bladder cancer and evaluation of aggressiveness and malignancy of bladder cancer. Thereby, the physician can arrange an optimized treatment to achieve the best therapeutic effect. | 08-11-2011 |
20120295288 | SEROLOGICAL MARKER FOR DETECTING PANCREATIC CANCER AND A METHOD FOR USING THE SEROLOGICAL MARKER - UL16 binding protein 2 (ULBP2) is a protein overexpressed in pancreatic cancer tissues, and the ULBP2 levels are significantly higher in pancreatic cancer patients than those in healthy controls. This invention provides a method to detect pancreatic cancer using ULBP2 as a serological marker. The combination of ULBP2 and CA19-9 promotes the efficacy of pancreatic cancer detection. When measuring the blood ULBP2 levels in patients with other cancer types, including colorectal carcinoma, nasopharyngeal carcinoma and gastric cancer illustrates the blood ULBP2 levels are higher in patients with pancreatic cancer than other cancer types. | 11-22-2012 |